A COVID-19 Derived Proteomic Risk Signature Discriminates Severity of Respiratory Failure in Patients with Influenza Pneumonia
Christopher V. Cosgriff(University of Pennsylvania), Nuala J. Meyer(Translational Therapeutics (United States)), C.A.G. Ittner(University of Pennsylvania), Ariel R. Weisman(University of Pennsylvania), Todd A. Miano(University of Pennsylvania), Divij Mathew(Parker Institute for Cancer Immunotherapy), Brian J. Anderson(University of Pennsylvania), Tiffanie K. Jones(University of Pennsylvania), H.M. Giannini(Lung Institute), Alexander C. Huang(University of Pennsylvania), M.G.S. Shashaty(University of Pennsylvania), John P. Reilly(University of Pennsylvania), T. Dunn(Hospital of the University of Pennsylvania)
Cited by 0
Related Papers
Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications
|Science|2020|1.7k
ESICM guidelines on acute respiratory distress syndrome: definition, phenotyping and respiratory support strategies
|Intensive Care Medicine|2023|855
Comprehensive mapping of immune perturbations associated with severe COVID-19
|Science Immunology|2020|806